Expression of the sodium iodide symporter ( NIS ) gene in tumor cells may provide a novel mechanism for treating cancer. The NIS mediates the normal physiological transport of iodide across the thyroid cell membrane. This mechanism of iodide uptake has been used to both diagnose and treat thyroid cancer. Tissue expression of the NIS is largely limited to the thyroid; therefore, expression of the NIS gene in cancer cells would allow for specific iodine uptake, radioisotope accumulation, and treatment. In this study, we directly compared the human and rat NIS ( rNIS ) for their ability to concentrate radioisotope into human and rodent cancer cells. Keywords: sodium iodide symporter; gene therapy T he sodium iodide symporter (NIS ) is a transmembrane protein presented in thyroid cells that is responsible for the uptake and concentration of iodine into the thyroid gland. Following symporter transport, the iodine is concentrated in the thyroid at levels 20 -to 40 -fold higher than plasma levels. This sequestered iodine is then organified during the synthesis of essential thyroid hormones.
T he sodium iodide symporter (NIS ) is a transmembrane protein presented in thyroid cells that is responsible for the uptake and concentration of iodine into the thyroid gland. Following symporter transport, the iodine is concentrated in the thyroid at levels 20 -to 40 -fold higher than plasma levels. This sequestered iodine is then organified during the synthesis of essential thyroid hormones. 1 The unique ability of the NIS to facilitate the concentration of iodine makes the symporter gene a novel tool for cancer research. Thyroid iodide uptake has been well established in treating and diagnosing thyroid cancers. As a treatment, the uptake of a high -energy radioisotope, such as 131 I, results in the ablation of thyroid tumors. By transferring the NIS gene to nonexpressing tumor cells, with subsequent expression, a new mechanism of cell death using an already defined technique is possible. Therefore, cancer cells might be modified to concentrate radiolabeled iodine resulting in cell death and tumor ablation similar to current thyroid cancer treatments. Our group and others have previously shown that both NIS genes could effectively induce uptake of iodine into multiple human cancer cells lines using retroviral vectors, 2 DNA transfection, 3, 4 or adenoviral vectors. 5, 6 However, we were interested in directly comparing the rat and human NIS ( hNIS ) genes to determine if the human gene would offer more advantageous expression and symporter functional activity in human cancer cells. The rat NIS ( rNIS ) and hNIS genes were recently cloned and sequenced. 7, 8 The open reading frame (ORF ) of the rNIS gene is 1854 nucleotides resulting in a 618-amino -acid protein, whereas the hNIS gene ORF is 1929 bp and encodes a 643-amino -acid protein. A protein sequence comparison between the rNIS and hNIS proteins predicted an 84% amino acid homology. Current research models of NIS suggest that 13 transmembrane helices span the cell membrane with the amino terminus on the extracellular side and the carboxy terminus on the intracellular side. 9 Recent kinetic studies have demonstrated an ordered, simultaneous transport mechanism where Na + binds, followed by iodide binding. 10 Although expression of the human gene is primarily seen in the thyroid, hNIS gene expression has been documented in colon, ovary, mammary, stomach, and salivary gland tissues. 11, 12 Patients with relapsing cancers that occur after radiation therapy or that become resistant to chemotherapy represent a difficult clinical challenge. New techniques are urgently needed to treat these patients. Expression of the NIS gene by cancer cells will allow 131 I to be concentrated in the same cells. This method of antitumor therapy should have a potent bystander effect because 131 I energy can travel 7 mm in tissues from the point of radionuclide decay. The iodideconcentrating ability of the rNIS and hNIS genes has been reported separately and was shown to induce iodine uptake into a wide variety of tumor cells. 2 -6 This is the first direct comparison between the two NIS genes from different species using the same vector backbone and target cells. We cloned the rNIS and hNIS genes into the retroviral vector backbone and transduced multiple cancer cell lines in parallel. Surprisingly, the experiments clearly showed that transfer of the rNIS gene provided superior accumulation of 125 I when compared to the hNIS gene. The rNIS gene resulted in an increased level of 125 I uptake when compared to the hNIS regardless of the cell line under investigation. Finally, cell killing was easily demonstrated in cells expressing either the rNIS or hNIS gene following exposure to 131 I. These data suggest that the rNIS gene delivery may provide superior radioisotope concentrating ability, which may translate into improved anticancer activity when combined with 131 I treatment.
Materials and methods

Cloning rNIS and hNIS gene into a retroviral vector
The cloning of the full -length rNIS gene into the retroviral vector pLXSN has been previously described. 2 The pL( rNIS )SN plasmid is a retroviral construct containing the rNIS gene. Dr S Jhiang ( The Ohio State University ) kindly provided the full -length hNIS gene cloned into the pcDNA3.1 vector (pcDNA -FL*hNIS ). The hNIS gene was EcoRI -digested from the pcDNA3.1 vector and ligated into pLXSN (kindly provided by AD Miller, Fred Hutchinson Cancer Research Center, Seattle, WA ). A recombinant plasmid pL(FL*hNIS )SN was sequenced through the insertion sites (Iowa State University Sequencing Facility, Ames, IA ). GP + E -86 cells (kindly provided by A Bank, Columbia University, NY ) were transfected with pL( rNIS ) SN or pL( FL*hNIS )SN using FuGene 6 2 ( Roche, Indianapolis, IN ). Supernatants from the transfected cells were used to transduce PA317 packaging cell line (kindly provided by AD Miller ). Transduced packaging cell lines were selected using G418 (1 mg /mL ) for 14 days. Supernatants from the PA317 cells containing packaged retroviral particles were used to transduce all other cell lines. For a negative control, a supernatant from the previously described LTK-OSN vector producer cell line ( PA317 ) was used to deliver the herpes simplex thymidine kinase ( HSVTK ) gene to A375 cells. 13 Cell culture and cell lines 786 -O renal cell carcinoma cells (ATCC, Manassas, VA ) were maintained in RPMI 1640 medium with 10 mM HEPES, 1 mM sodium pyruvate, and 10% fetal bovine serum ( FBS ) ( Life Technologies, Rockville, MD ). PC -3 human prostate adenocarcinoma cells (ATCC ) were maintained in Ham's F12K medium with 2 mM L -glutamine adjusted to contain 1.58 g/ L sodium bicarbonate and 10% FBS. A375 human melanoma cells, C6 rat glial cells, COS -7 monkey kidney fibroblast cells, SK -BR -3 and MCF -7 human breast adenocarcinoma cells (all from ATCC ), IGROV human ovarian (adenocarcinoma ) cells (kindly provided by J Benard), and PG13 and PA317 mouse fibroblast cells were maintained in DMEM with 10% FBS and 2 mM L -glutamine (D10 ) ( Life Technologies ). D1, used in the clonogenic assay, is the same as D10 but contains only 1% FBS. All cells were maintained at 5% CO 2 and 378C. A375 -transduced cells were cloned by limiting cell dilution. Briefly, a mixed single cell suspension of cells was diluted to 2.5 cells /mL. The cells were plated in 96 -well plates and screened for individual colonies.
Iodide uptake experiments
Iodide uptake was measured using the methods of Mandell et al. 2 Briefly, cells ( 5Â10 4 ) were seeded into 24 -well plates in D10. Following an 18-to 24-hour incubation period at 378C with 5% CO 2 , the medium was aspirated and the cells were washed with buffered Hank's Balanced Salt Solution ( B -HBSS; Life Technologies ).
14 Iodide uptake was initiated by adding 0.5 mL of B -HBSS containing 0.057 -0.345 nM carrier-free Na 125 I (Dupont NEN, Boston, MA ) and 5-300 M NaI to give a specific activity of 88-880 nCi /mL. For standard 125 I uptake assays, cells were incubated with radioisotope for 30 minutes ( 378C, 5% CO 2 ). For the time course assays, cell incubations with 125 I ranged from 20 to 120 minutes. Sodium perchlorate has been shown to effect as an inhibitor on the NIS function. 10, 14, 15 For sodium perchlorate inhibition studies, NaClO 4 ( Sigma, St. Louis, MO ) was added as a 10 -mM solution in B -HBSS to a final concentration of 30 M. The sodium perchlorate solution was added at the same time as the inhibitor-free solution described earlier. Reactions were rapidly terminated after the desired incubation time by removing the radioactive solution and rinsing the cells once with 0.8 mL of ice -cold B -HBSS. Cells were then lysed for 20 minutes with 0.5 mL of 1% Triton X -100 ( Sigma ) in B -HBSS and accumulated iodide was measured on a gamma counter (Wallac, Turku, Finland ). Using a separate 24 -well plate, cells were harvested and counted at the time of the experiment to determine the quantity of cells per well.
Membrane fraction preparation
Membrane fractions were prepared from nontransduced A375 cells and stably transduced and selected for high NIS activity A375 rNIS 3G11 clone, as previously described. 16 Briefly, cells were plated on T-175 flasks, washed with PBS, harvested, and homogenized in ice -cold buffer containing 250 mM sucrose, 10 mM HEPES (pH 7.5 ), 1 mM EDTA, 10 g /mL leupeptin, 10 g/mL aprotinin, and 1 mM phenylmethylsulfonyl fluoride (Sigma). The homogenate was centrifuged twice at 500Âg for 10 minutes at 48C. An additional centrifugation at 100,000Âg was performed for 20 minutes, and the pellet was resuspended in an appropriate volume of ice -cold buffer containing 250 mM sucrose, 10 mM HEPES (pH 7.5), and 1 mM MgCl 2 .
Western blot analysis
Aliquots of membranes ( 20-30 g ) prepared from nontransduced A375 cells and stably transduced A375 rNIS
Cancer Gene Therapy rNIS provides more efficient uptake than hNIS LM Heltemes et al 3G11 were diluted with 5Â loading buffer and heated at 378C for 30 minutes before being separated by SDS -PAGE. After gel electrophoresis for 1 hour, the proteins were transferred to a nitrocellulose membrane using electroblotting. After blotting, membranes were preincubated for 1 hour in the buffer containing 20 mM Tris ( pH 7.5 ), 137 mM NaCl, 5% nonfat dried milk, and 0.05% Tween -20 to block nonspecific proteins binding. Membranes were then incubated with affinity-purified rNIS -specific antibody directed against amino acid residues 603 -618 (kindly provided by N Carrasco, Albert Einstein College of Medicine, NY ). After washing, the membranes were incubated with antirabbit antibodies conjugated with alkaline phosphatase ( Sigma ). BCIP /NBT ( Sigma ) was used as a substrate for alkaline phosphatase.
Slot blot and Northern blot analyses
Total RNA was isolated from transduced and nontransduced cell lines using the RNeasy Kit ( Qiagen, Valencia, CA ). For the Northern blot, 10 g of total RNA isolated from A375 cells was loaded per well on a 1.25% formaldehyde gel ( FMC BioProducts, Rockland, ME ) and 10 g of total RNA from MCF -7 and C6 cells was loaded on a 1% formaldehyde gel. For slot blot analysis, 10 g of total RNA treated with Dnase I was used. The Northern and slot blot analyses were performed following standard procedures. 17 The Hybond 2 -N + nylon transfer membrane was used ( Amersham Pharmacia Biotechnologies, Piscataway, NJ ). The hNIS probe was created by PCR amplification of the 5 0 -end of the hNIS gene (sense: 5 0 -CTTCTGAAC-TCGGTCCTCAC; antisense: 5 0 -TCCAGAATGTATAGC-GGCTC ). 12 The rNIS probe was generated by PCR amplification of the 5 0 -end of the rNIS gene (sense: 5 0 -TAC GGC GTG TTC GCG ACC AT; antisense: 5 0 -AAG TAC TGC AGC GTC CCG CA ).
Each probe was labeled using a random primed DNA labeling method ( Roche ). A full -length human b -actin cDNA (Clontech, Palo Alto, CA ), was labeled and used to ascertain equivalent levels of RNA loading.
I clonogenic assays
Cells were plated in six -well plates based on growth rate ( MCF -7, 1000 and 1500 cells/well; C6, 500 and 1000 cells/well). Each cell concentration was plated in triplicate. Duplicate plates were made -one for the addition of 131 I and one as a control plate. Cells were allowed to attach at 378C, 95% humidity, and 5% CO 2 for 18 hours in D10, after which the medium was aspirated from the wells and cells were rinsed with HBSS. One milliliter of D1 containing 20 Ci of 131 I ( DuPont NEN ) or radioisotopefree medium was added to each well and the plates were incubated for either 12 or 24 hours. The radioactive medium was removed, cells were rinsed with HBSS, and D10 was added to each well. The medium was replaced once a week. When the colonies reached a size greater than 50 cells per colony, the cells were fixed with methanol and acetic acid (3:1 ), stained with crystal violet, and counted.
Results
Functional transduction of rNIS into multiple cancer cell lines ( uptake assays )
The rNIS gene had previously been cloned into a retroviral vector. 2 We cloned the hNIS gene into the same retroviral vector. The rNIS vector is called pL( rNIS )SN and the hNIS vector is referred to as pL( FL*hNIS )SN. As a control, we also transduced cells with a retroviral construct containing the HSVTK gene.
13 A375 human melanoma cells, C6 rat glial cells, COS -7 monkey kidney fibroblast cells, IGROV human ovarian (adenocarcinoma ) cells, SK -BR -3 and MCF -7 human breast ( adenocarcinoma ) cells, 786-O renal cell carcinoma cells, PC -3 human prostate adenocarcinoma cells, and PG13 and PA317 mouse fibroblast cells were stably transduced with either pL(rNIS)SN and pL ( FL*hNIS )SN. Iodine uptake assays were performed to determine the level of perchlorate -sensitive iodine uptake. Nontransduced A375 cells or A375 cells transduced with a TK -containing retrovirus demonstrated identical low iodine uptake ( data not shown ). Nontransduced cells were then used as a negative control for all subsequent experiments. Figure 1 shows the increase in iodide uptake following transduction of four cell lines ( SK -BR -3, MCF -7, C6, and COS -7). The transduced cells demonstrated a 3 -to 13 -fold increase in perchlorate -sensitive iodine uptake showing that it is the NIS -specific 125 I transport (Table 1 ) . A comparison between nontransduced and transduced cells showed a 3 -to 67-fold iodine uptake increase. The inhibition level of 125 I uptake for the rNIS was highest in A375. The range of iodine uptake for the hNIS was a 3 -fold increase in IGROV cells to a 12 -fold increase in COS -7 cells. However, the difference is more dramatic when comparing transduced to nontransduced cells, than when comparing inhibition sensitivity. The rNIS gene delivery showed a range in 125 I uptake from 8 -fold (IGROV ) to 67 -fold (COS -7 ). The difference was also high in the cells expressing the hNIS gene, where a range from 3 -fold ( IGROV ) to 22-fold (COS -7) was observed.
The large variability of radioiodine uptake observed in the various cell lines used in this study may be due to several reasons, and we will address this in the discussion. However, despite this, iodine uptake was uniformly higher with the rNIS gene when compared to the human gene. Although the highest fold increase (5.1 -fold ) was observed in rat C6 glioma cells, the rNIS activity always was superior in all types of cell lines studied, including human, rat, and murine tumor cells, as well as fibroblasts. In human cancer cells containing the rNIS gene, iodine uptake was clearly superior, ranging from a 30% enhanced uptake in PC -3 prostate cells to a 310% increased uptake in SK -BR -3 cells. All of these data were generated with a mixed population of transduced cells, and not individual cell clones.
Limiting dilution cloning for increased 125 
I uptake ability
Human melanoma cell line (A375 ) stably transduced with pL(rNIS)SN was subjected to limited dilution cell cloning. Selected clones were grown and assayed to determine the relative perchlorate-sensitive 125 I uptake. Six of 40 clonally selected cell populations displayed a maximum of a 2 -Cancer Gene Therapy rNIS provides more efficient uptake than hNIS LM Heltemes et al fold increase in 125 I uptake when compared to the mixed population. Figure 2A shows the 125 I uptake data of 10 of 40 clones tested. Clone A375 rNIS 3G11 exhibited high iodine uptake in comparison to a mixed population of transformed cells, and was therefore used as the positive control in all subsequent experiments (Fig 2B ) . Thus, variability of iodine uptake in individual transduced tumor cell clones occurred as would be predicted because the retroviral vector integrates randomly into the genomic DNA.
Northern and slot blot analyses of gene transcripts
Total RNA was isolated from transduced and nontransduced cell lines to determine NIS mRNA levels. RNA was transferred using a suction slot blot apparatus and the Cancer Gene Therapy rNIS provides more efficient uptake than hNIS LM Heltemes et al Cancer Gene Therapy rNIS provides more efficient uptake than hNIS LM Heltemes et al membranes were hybridized with rNIS, hNIS, and b -actin DNA probes. Despite DNA sequence homology, there was very little cross -hybridization between the rNIS and hNIS nucleic acids (Fig 3 ) . A375, PA317, and C6 expressed the highest levels of the rNIS mRNA. Northern blot analysis confirmed the slot blot analysis. A comparison of the A375 rNIS 3G11 clone and the A375 rNIS mixed population showed slightly higher levels of mRNA expression with this clone ( Fig 2C ) . Expression of the hNIS mRNA is low in A375 cells but is still higher than in other cell lines ( data not shown ). Northern blot for stably transduced MCF-7 and C6 cell lines also demonstrates low levels of hNIS transcripts. Thus, low hNIS mRNA levels could partly explain decreased iodine uptake observed in cells transduced with hNIS gene. However, different molecular mechanisms of regulation of human and rat gene expression could be involved in this discrepancy, as well.
Western blot analysis
Western Blot analysis was performed on cellular membranes isolated from A375 rNIS 3G11 clone with highest NIS activity, as well as membranes isolated from nontransduced A375 cells. An antibody recognizing the COOH terminus of the rNIS protein was used. A375 rNIS 3G11 cells were positive for symporter protein expression, whereas the nontransduced A375 NV cells were negative for symporter expression (Fig 4 ) . This shows that the specific iodine uptake in rNIS-expressing cells is due to the expression and functionality of the symporter protein. The same experiment was performed on cells expressing the human symporter; however, the antihuman symporter antibody was not sensitive enough to obtain definitive results.
Time course assay
The time course assay for iodide uptake was performed in MCF -7 breast carcinoma cells transduced with either the rNIS or hNIS gene. Tumor cells were incubated for 20-120 minutes with 30 M NaI and 0.115 nM Na 125 I ( 294 nCi /mL ) in B -HBSS. An essential increase in iodide accumulation in the first 20 -30 minutes with rNIStransduced cells was previously reported. 2 The retroviral Western blot analysis of membranes isolated from A375 NV and A375 rNIS 3G11 clone. Membranes ( 30 g of total protein ) were loaded onto 12% PAAG. Affinity -purified rNIS -specific antibody directed against amino acid residues 603 -618 were used to demonstrate the NIS expression in transduced cells.
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delivery of the hNIS gene to MCF -7 cells results in
125 I uptake at a lower rate than observed in MCF -7 cells with the rNIS gene, and reaches a steady state of uptake at approximately 20 minutes (Fig 5 ) . The magnitude of iodine uptake in these human breast cancer cells was approximately 4 -fold higher with the rNIS gene when compared to the human gene. The cells remained in this steady state for both genes for up to 120 minutes ( data not shown ).
Clonogenic assays
Clonogenic assays using a rat glial cell line ( C6 ) and a human breast cell line ( MCF -7 ) were performed to determine cell survival following exposure to 131 I. Transduced and nontransduced cells were seeded onto plates and each well was treated with 20 Ci of 131 I for either 12 or 24 hours. Following 131 I exposure, cells were grown until colonies reached a size of at least 50 cells. Survival of transduced cells was decreased in both cell lines ( Fig 6) , with the greatest 131 I lethal effect on MCF -7 cells expressing human or rNIS genes. Cell survival for the nontransduced MCF -7 cells was approximately 90% for both the 12-and 24 -hour exposure times. Retroviral delivery of rNIS and hNIS genes to MCF -7 cell line resulted in approximately 30% cell survival at both 12 and 24 hours. At 12 hours, all nontransduced C6 cells survived, whereas only 60% of the rNIS -transduced cells and 58% of the hNIS -transduced cells survived. Similar percentages were seen at the 24 -hour time point.
Discussion
Radioisotope concentrator gene therapy is a novel class of cancer gene therapy. This approach is based upon the unique ability of the NIS highly expressed in the thyroid to specifically concentrate iodine in thyroid cells. For over 40 years, thyroid cancers have been treated using 131 I radionuclide for tumor ablation. 18 The ability to localize radiation within the target tumor mass or cancerous region would provide a new, specific approach to eliminating cancer cells. Moreover, the ability to concentrate large doses of radiotherapy locally may provide a distinct advantage against relatively radioresistant tumors. The NIS concentrates iodine in the thyroid, making the NIS gene an ideal tool for specific radiotherapy for many different types of cancers.
Spitzweg et al 19 have demonstrated tumor regression after the administration of 131 I in animals with human tumor xenografts expressing the hNIS gene under control of the PSA promoter. The goal of our study was to compare the functional activity of rNIS and hNIS. Using retroviruses containing the NIS gene, we stably transduced a wide variety of cancer cell lines. We demonstrated 125 I uptake by both the rat and human symporter in every cancer cell line that was transduced. Iodine uptake ranged from 3 -to 67-fold higher in NIS -transduced cells when compared to either nontransduced cells, or cells that were transduced with a control retrovirus. Although the NIS gene was driven by the same promoter in all the cell lines, it appears that iodine uptake varies greatly between cell lines. The large variability of radioiodine uptake observed in the various cell lines used in this study may be due to several reasons. In our previous data, we have determined variability of LTR function in different tissue cell types. 20, 21 Differences in cellular growth rates and mRNA turnover may affect NIS gene expression and transcription, respectively. Moreover, variability in posttranslational modification and transport of NIS to the plasma membrane between tumor lines may account for the observed differences in iodine uptake.
To further examine the effect of the NIS gene and to determine if it was possible to increase iodine uptake, limiting dilution cloning of rNIS -transduced A375 cells was performed to create clonal populations of cells. This allowed us to study cell populations with single retroviral integration sites. Varying levels of iodine uptake demonstrated the cellto -cell variability following clonal selection. The NIS mRNA expression level was slightly higher in one of the clones (3G11 ) that accumulated iodine at a higher level than the mixed population. This increased RNA transcript suggests that increased expression between the clone and the mixed cell population may be a result of the retroviral integration site. Xu et al 22 have shown that following retroviral transduction, the insertion site may affect the expression level of the transgene. Insertion of the transgene into a region of low transcriptional activity may result in decreased expression and/ or transcript stability. This result also suggests that it is possible to increase iodine uptake activity by increasing gene transcript levels. However, for the Cancer Gene Therapy rNIS provides more efficient uptake than hNIS LM Heltemes et al comparisons between the rNIS and hNIS genes, only mixed populations of transduced selected cells were employed. A major difference was observed within each cell line when comparing iodine uptake facilitated by the rNIS and hNIS gene. The rNIS gene expression consistently yielded higher iodine uptake levels in every cell line that was tested. Even when the hNIS gene was expressed in human cancer cell lines, the rat symporter still concentrated iodine at a higher level in the same cell line. Low hNIS mRNA levels could partly explain decreased iodine uptake observed in cells transduced with hNIS gene. However, different molecular mechanisms of regulation of human and rat gene expression could be involved in this discrepancy, as well. Furthermore, there were some major differences in predicted hydrophilic and hydrophobic regions of human and rat protein structure and orientation inside the cellular plasmic membrane. 23 The hNIS protein sequence predicts that a more extensive intracellular domain exists in the hNIS protein when compared to the rNIS protein. 8 These differences in protein structure may be related to the differences in symporter function described here.
The hNIS gene is expressed at basal levels in additional tissues other than the thyroid. 11, 12, 24 These tissues include the salivary gland, stomach, mammary gland, colon, and ovary. We did not observe 125 I uptake in any of the nontransduced cancer cell lines tested. A recent report has shown relatively increased function of the NIS in some cancer cells without the exogenous introduction of the gene. 24 Interestingly, enhanced uptake was observed consistently in several breast cancer cell lines from de novo NIS gene expression. In the current study, iodine uptake only occurred in retrovirally transduced cell lines expressing the NIS gene. A time course assay using MCF -7 breast carcinoma cells was performed to study the uptake of iodine over time. Iodine uptake increased initially and remained steady up to 120 minutes after the addition of iodine (data not shown ). This is important when considering radiation treatment utilizing the NIS technology. The specific nature of NIS iodine uptake should result in little systemic side effects when used as a form of gene therapy. This has been further confirmed by many years of experience with 131 I treatment in thyroid cancer patients in whom little or no systemic toxicity was observed.
This study has demonstrated that the NIS facilitates specific iodine uptake in various cancer cell lines in vitro. For uptake assay, we used 125 I, a lower-energy gamma emitter that is not radiotoxic to cells. In order to study the NIS suicide gene effect in vitro, it was necessary to use 131 I. The physical characteristics of 131 I decay allow radiation penetration and delivery within a local area averaging 7 mm from the point of decay. These high -energy b particles ( E 1 = 0.608 MeV; E 2 = 0.315 MeV ) can penetrate biological tissue and cause significant bystander killing by irradiating adjacent cells within tumor mass. Clonogenic assays were performed on two cancer cell lines MCF -7 and C6. We have previously published results for a time course of 125 I uptake and clonogenic assay for A375 melanoma cells. 2 Both NIStransduced cell lines showed varying levels of cell death in response to iodine uptake with minimal to no side effects on nontransduced cells. MCF-7 cells showed the highest level of cell killing, with only 28% survival after 24 hours of 131 I iodine exposure. The 125 I uptake differences with the rat and human symporter translated to a modest increased cell death using 131 I in rNIS -transduced cell lines. This difference in cell death was only observed at the 12 -hour time point for C6 cells. As previously discussed, 2 the geometry of radiation for single cell clonogenic assays does not effectively correlate to cell killing effect by 131 I because the path length of iodine energy deposition (7 mm ) is much greater than the cell diameter.
In conclusion, the rat ( or human ) NIS can be used as an effective method for effective delivery of radioactive iodine toxic doses to specific tissues. To translate these findings into human clinical trials for malignancies will be challenging. The efficiency of gene transfer into solid tumors in humans has been uniformly lower than that observed in rodent models of implanted tumors. This barrier to efficient gene transfer into human tumor masses remains to be the most challenging technical problem. Therefore, employing the most potent transgene, especially in circumstances of lower gene transfer efficiency, is critical. A number of technical issues need to be addressed to bridge these initial findings to the clinic. Issues that still need to be resolved include identifying which tumor types would be most appropriate for this procedure, and what is the best method for in vivo gene delivery and expression. The relative radiosensitivity of the tissue of interest is important, and there are clearly differences among malignant cell types.
25 Surprisingly, our results show significant variability of NIS transgene function between various human tumor cell lines. Whether the greater iodine uptake observed in vitro with the rNIS gene will enhance potential in vivo therapy is, as yet, unknown. Further surveys are required to assess what malignancies will be the best targets for this approach. Continued research to combine NIS gene therapy and iodide radioisotopes may yet provide a powerful treatment to successfully ablate a variety of lethal neoplasms while minimizing systemic toxicity.
